Evidence map›Paper›PMID 26322580›Full record

ArticleNature medicine2015

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Holly Janes, Joshua T Herbeck, Sodsai Tovanabutra, Rasmi Thomas, Nicole Frahm, Ann Duerr, John Hural, Lawrence Corey, Steve G Self, Susan P Buchbinder and 13 more

Abstract read
In one paragraph

Article in Nature medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Phylogenetic Analysis of Human Immunodeficiency Virus from People Who Inject Drugs in Indonesia, Ukraine, and Vietnam: HPTN 074.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2019
    Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Holly JanesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Joshua T HerbeckDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Sodsai TovanabutraUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Rasmi ThomasUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Nicole FrahmVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ann DuerrVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
John HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Steve G SelfVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Susan P BuchbinderVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID http://orcid.org/0000-0003-2276-7117
Robert J O'ConnellRoyal Thai Army Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Robert M ParisUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Supachai Rerks-NgarmThai Ministry of Public Health, Nonthaburi, Thailand.
Sorachai NitayaphanRoyal Thai Army Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Punnee PitisuttihumFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Jaranit KaewkungwalFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Merlin L RobbUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
James I MullinsDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Jerome H KimUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Morgane RollandUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Statistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7M
FILARIASIS REPOSITORY RESEARCH SERVICEN01AI002642 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI MC CALL, JOHN W · 1985 to 1987
–
NIAID NIH HHS 2R37AI05465-10NIAID NIH HHS AI41505NIAID NIH HHS R37 AI054165NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS Y01 AI002642NIAID NIH HHS Y1-AI-2642-12
6 · The paper itself

Abstract

Given the variation in the HIV-1 viral load (VL) set point across subjects, as opposed to a fairly stable VL over time within an infected individual, it is important to identify the characteristics of the host and virus that affect VL set point. Although recently infected individuals with multiple phylogenetically linked HIV-1 founder variants represent a minority of HIV-1 infections, we found--n two different cohorts--hat more diverse HIV-1 populations in early infection were associated with significantly higher VL 1 year after HIV-1 diagnosis.

Indexed as

Founder EffectViral LoadHIV-1HIV InfectionsHumans

Identifiers

PMID26322580
PMCPMC4598284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.